| Autor: |
Morel GR; Institute for Biochemical Research-Histology B, Faculty of Medicine, National University of La Plata, Argentina., Reggiani PC, Console GM, Rimoldi OJ, Vesenbeckh SM, Garcia-Bravo MM, Rodriguez SS, Brown OA, Goya RG |
| Jazyk: |
angličtina |
| Zdroj: |
Current gene therapy [Curr Gene Ther] 2008 Feb; Vol. 8 (1), pp. 49-53. |
| DOI: |
10.2174/156652308783688518 |
| Abstrakt: |
The aim of the present article is to discuss the potential of gene therapy for thymic hormones as a novel therapeutic strategy to treat dyshomeostatic conditions associated with congenital athymia or hypofunction of the endocrine thymus. Recent studies using an adenoviral vector harboring a synthetic gene for the thymic peptide thymulin are reviewed. This adenoviral vector was injected intramuscularly in thymectomized and nude mice as well as in thymectomized rats. Transduced myocytes acted as an ectopic source of thymulin thus restoring circulating thymulin levels to normal values. This restorative effect was long lasting (several months) even though an adenoviral vector was used. In the rat brain, adenovirally-mediated delivery of the synthetic gene for thymulin achieved longer expression than in the case of adenovirally-delivered reporter genes, which is consistent with the reported antiinflammatory activity of thymulin in the brain. Furthermore, neonatal thymulin gene therapy in nude female mice was able to prevent the pituitary and ovarian alterations that typically occur in this mutant after puberty. Neonatal thymulin gene therapy in nude mice was able to prevent some of the alterations in lipid metabolism that develop during adult life in congenitally athymic mice. We conclude that the availability of the above biotechnological tools should boost basic studies on the molecular biology of thymulin and should also allow an assessment of the potential of gene therapy to restore circulating thymulin levels in thymodeficient animal models and eventually, in humans. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
